Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX110 in relapsed/refractory B-cell malignancies
NCT04035434Phase 2Terminated
- Sponsor
- CRISPR Therapeutics
- Start
- Jul 2019
- Primary completion
- Oct 2024
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 6
01
Overview
A Phase 2 trial of CTX110 in non-Hodgkin lymphoma (NHL), B cell acute lymphoblastic leukemia (B-ALL), sponsored by CRISPR Therapeutics. Started Jul 2019; status: terminated.
02
Drugs
CTX110
03
Conditions
non-Hodgkin lymphoma (NHL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04035434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04035434.